Chronic Hepatitis B Market Forecast 2024-2033: Growth Rate, Drivers, And Trends | Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation

The Chronic Hepatitis B Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Chronic Hepatitis B Market:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

According to The Business Research Company’s Chronic Hepatitis B Global Market Report 2024, The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%.  The growth in the forecast period can be attributed to expansion in emerging markets, growing government policies and funding, improved diagnostics and screening, rising healthcare expenditure, increasing strategic collaborations and partnerships, a growing aging population, and growing public awareness campaigns. Major trends in the forecast period include a shift towards curative therapies, expansion in emerging markets, enhanced diagnostics and screening, partnerships and collaborations, and a and a focus on patient-centric care.

The high prevalence of chronic hepatitis B infection is expected to propel the growth of the chronic hepatitis B virus market going forward. Hepatitis B is a liver infection brought on by the hepatitis B virus (HBV), which is prevented through vaccination. The increase in hepatitis B infection rates is due to a combination of factors, particularly in low- and middle-income countries, due to low vaccination coverage leading to higher transmission rates as large portions of the population remain unprotected. Rising hepatitis B infection rates can increase demand for diagnostic tests and treatment options. For instance, in December 2022, according to the European Centre for Disease Prevention and Control, a Sweden-based agency for strengthening Europe’s defenses against infectious diseases, hepatitis B virus (HBV) infection was recorded in 16,187 cases in 30 Eastern European Member States in 2021. Further, the total cases 15,380 equal a crude rate of 4.7 cases per 100,000 people, compared to 14,332 in 2020. Therefore, the high prevalence of hepatitis B infection will drive the chronic hepatitis B virus market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

The chronic hepatitis b market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators
2) By Gender: Male, Female
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Major companies operating in the chronic hepatitis B market are adopting a strategic partnership approach to enhance their technological capabilities and market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations combining their resources, expertise, and efforts to achieve common goals or objectives. For instance, in January 2021, Gilead Sciences Inc., a US-based biopharmaceutical company, collaborated with VIR Biotechnology, a U.S.-based biotech company, to explore novel combination therapies to achieve a functional cure for chronic hepatitis B virus (HBV). They will commence a Phase 2 trial assessing various combinations of Gilead’s investigational TLR-8 agonist, selgantolimod, Vir’s investigational siRNA, VIR-2218, and a commercially available PD-1 antagonist. Additionally, treatment-experienced patients may receive Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF). The trial’s primary goal is determining the percentage of patients achieving a functional cure, characterized by the off-therapy disappearance of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

The chronic hepatitis b market report table of contents includes:
1. Executive Summary
2. Chronic Hepatitis B Market Characteristics
3. Chronic Hepatitis B Market Trends And Strategies
4. Chronic Hepatitis B Market – Macro Economic Scenario
5. Global Chronic Hepatitis B Market Size and Growth
…………..
32. Global Chronic Hepatitis B Market Competitive Benchmarking
33. Global Chronic Hepatitis B Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Chronic Hepatitis B Market
35. Chronic Hepatitis B Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:
https://topprnews.com/modular-trailer-market-forecast/
https://topprnews.com/global-organic-olive-oil-market-report/
https://topprnews.com/polypropylene-dual-flap-dispensing-closure-market-report/
https://goodprnews.com/modular-trailer-market-share/
https://goodprnews.com/global-organic-olive-oil-market-analysis/
https://goodprnews.com/polypropylene-dual-flap-dispensing-closure-market-share/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model